Publications

du GRPSO

Publications 2014
Les publications du GRPso / 2014

Sbidian E, Eftekahri P, Viguier M, Laroche L, Chosidow O, Gosselin P, Trouche F, Bonnet N, Arfi C, Tubach F, Bachelez H National Survey of Psoriasis Flares after 2009 Monovalent H1N1/Seasonal Vaccines. Dermatology. 2014;229(2):130-5.

Tauber M, Buche S, Reygagne P, Berthelot JM, Aubin F, Ghislain PD, Cohen JD, Coquerelle P, Goujon E, Jullien D, Brixi H, Jeudy G, Guennoc X, Martin A, Brénaut E, Hoppé E, Bertolotti A, Bardin T, Delaporte E, Allez M, Bachelez H, Seneschal J, Viguier M; Groupe de Recherche sur Psoriasis de Société Française de, Dermatologie; Club Rhumatismes et Inflammation (CRI); Groupe d'études thérapeutiques des affections inflammatoires du tube digestif (GETAID). Alopecia areata occurring during anti-TNF therapy: a national multicenter prospective study. J Am Acad Dermatol. 2014 Jun;70(6):1146-9.

Viguier M, Livideanu C, Beylot-Barry M, Richard MA, Paul C, Bachelez H, Aubin F; Groupe de Recherche sur le Psoriasis. Observational case series on a group of psoriasis patients who failed to respond to any TNF blockers. J Dermatolog Treat. 2014 Feb;25(1):75-7.

Baroudjian B, Viguier M, Battistella M, Beneton N, Pagès C, Gener G, Bégon E, Bachelez H. Psoriasis associated with idiopathic CD4+ T-cell lymphopenia: a regulatory T-cell defect? Br J Dermatol. 2014 Jul;171(1):186-9.

Lebwohl MG, Bachelez H, Barker J, Girolomoni G, Kavanaugh A, Langley RG, Paul CF, Puig L,Reich K, van de Kerkhof PC. Patient perspectives in the management of psoriasis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis Survey. J Am Acad Dermatol 2014 ; 70: 871-81.

Le Moigne M, Sommet A, Lapeyre-Mestre M, Bourrel R, Molinier L, Paul C, Montastruc JL. Healthcare cost impact of biological drugs compared with traditional systemic treatments in psoriasis: a cohort analysis in the French insurance database. J Eur Acad Dermatol Venereol 2014;28:1235-44.

Paul C, Lacour JP, Tedremets L, Kreutzer K, Jazayeri S, Adams S, Guindon C, You R, Papavassilis C, the JUNCTURE study group. Efficacy, safety and usability of secukinumab administration by autoinjector/pen in psoriasis: a randomized, controlled trial (JUNCTURE). J Eur Acad Dermatol Venereol, 2014.

Paul C, Puig L, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Lavie F, Mistry S, Bergmans P, Barker J, Reich K, TRANSIT Investigators. Transition to ustekinumab in patients with moderate-to-severe psoriasis and inadequate response to methotrexate: a randomized clinical trial (TRANSIT). Br J Dermatol, 170,425-34, 2014.

Paul C, Reich K, Gottlieb AB, Mrowietz U, Philipp S, Nakayama J, Harfst E, Guettner A, Papavassilis C, the CAIN457A2211 study group. Secukinumab improves hand, foot and nail lesions in moderate-to-severe plaque psoriasis: subanalysis of a randomized, double-blind, placebo-controlled, regimen-finding phase 2 trial. J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1670-5..

Reich K, Puig L, Paul C, Kragballe K, Luger T, Lambert J, Chimenti S, Girolomoni G, Nicolas JF, Rizova E, Brunori M, Mistry S, Bergmans P, Barker J, TRANSIT Investigators. One-year safety and efficacy of ustekinumab and results of dose adjustment after switching from inadequate methotrexate treatment: the TRANSIT randomized trial in moderate-to-severe plaque psoriasis. Br J Dermatol 2014;170:435-44.

Richard MA,Barnetche T,Rouzaud M,Sevrain M,Villani AP,Aractingi S,Aubin F,Beylot-Barry M,Joly P,Jullien D,Le Maître M,Misery L,Ortonne JP,Cantagrel A,Paul C.Evidence-based recommendations on the role of dermatologists in the diagnosis and management of psoriatic arthritis: systematic review and expert opinion. J Eur Acad Dermatol Venereol, 28 Suppl 5, 3-1, 2014.

Richard MA, Paul C. Risk factors, diagnosis and management of psoriatic arthritis: systematic literature reviews and expert opinion of a panel of dermatologists. J Eur Acad Dermatol Venereol 2014; 28 Suppl 5:1-2.

Richette P, Tubach F, Breban M, Viguier M, Bachelez H, Bardin T, Dougados M. Psoriasis and phenotype of patients with early inflammatory back pain. Ann Rheum Dis. 2013 Apr;72(4):566-71.

Rouzaud M, Sevrain M ,Villani AP, Barnetche T, Paul C, Richard MA, Jullien D, Misery L, Le Maître M, Aractingi S, Aubin F, Joly P, Cantagrel A, Ortonne JP, Beylot-Barry M. Is there a psoriasis skin phenotype associated with psoriatic arthritis? Systematic literature review. J Eur Acad Dermatol Venereol 2014;28 Suppl 5:17-26.

Setta-Kaffetzi N, Simpson MA, Navarini AA, Patel VM, Lu HC, Allen MH, Duckworth M, Bachelez H, Burden AD, Choon SE, Griffiths CE, Kirby B, Kolios A, Seyger MM, Prins C, Smahi A, Trembath RC, Fraternali F, Smith CH, Barker JN, Capon F. AP1S3 mutations are associated with pustular psoriasis and impaired Toll-like receptor 3 trafficking. Am J Hum Genet. 2014 May 1;94(5):790-7.

Sevrain M, Richard MA, Barnetche T, Rouzaud M, Villani AP, Paul C, Beylot-Barry M, Jullien D, Aractingi S, Aubin F, Joly P, Le Maitre M, Cantagrel A, Ortonne JP, Misery L. Treatment for palmoplantar pustular psoriasis: systematic literature review, evidence-based recommendations and expert opinion. J Eur Acad Dermatol Venereol, 28 Suppl 5, 13-6, 2014

Sevrain M, Villani AP, Rouzaud M, Barnetche T, Paul C, Richard MA, Beylot-Barry M, Jullien D, Aractingi S, Aubin F, Joly P, Le Maitre M, Cantagrel A, Ortonne JP, Misery L. Treatment (biotherapy excluded) of psoriatic arthritis: an appraisal of methodological quality of international guidelines. J Eur Acad Dermatol Venereol 2014; 28 Suppl 5:33-9.

Tauber M, Viguier M, Alimova E, Petit A, Lioté F, Smahi A, Bachelez H. Partial clinical response to anakinra in severe palmoplantar pustular psoriasis. Br J Dermatol. 2014 Sep;171(3):646-9.

Villani AP, Rouzaud M, Sevrain M, Barnetche T, Paul C, Richard MA, Beylot-Barry M, Misery L, Joly P,  Aractingi S, Aubin F, Le Maître M, Cantagrel A, Ortonne JP, Jullien D. Symptoms dermatologists should look for in daily practice to improve detection of psoriatic arthritis in psoriasis patients: an expert group consensus. J Eur Acad Dermatol Venereol 2014;28 Suppl 5:27-32.